Adverse effects of reduced-dose d-penicillamine in children with mild- to-moderate lead poisoning

Annals of Pharmacotherapy

Volumn 34, Issue 1, 2000, Pages 15-18

  Shannon, Michael W ^a,b   Townsend, Meaghan Kennedy ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Chelation; D penicillamine; Lead poisoning

Indexed keywords

DIPHENHYDRAMINE; PENICILLAMINE;

ARTICLE; CHELATION THERAPY; CHILD; CHILDHOOD INJURY; DRUG ERUPTION; HUMAN; LEAD POISONING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RASH;

EID: 0033979973     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19084     Document Type: Article

References (33)

1. Centers for Disease Control. Update: blood lead levels - United States, 1991-1994. MMWR Morb Mortal Wkly Rep 1997;46:141-5.
2. Bellinger D. Teratogen update: lead. Teratology 1994;50:367-73.
3. Rosen JF, Chesney RW, Hamstra A, DeLuca H, Mahaffey KR. Reduction in 1,25-dihydroxyvitamin D in children with increased lead absorption. N Engl J Med 1980;302:1128-30.
4. Verberk MM, Willems TE, Verplanki AJ, DeWolff FA. Environmental lead and renal effects in children. Arch Environ Health 1996;51:83-7.
5. McDonald JA, Potter NU. Lead's legacy? Early and late mortality of 454 lead-poisoned children. Arch Environ Health 1996;51:116-21.
6. Wetmur JG. Influence of the common human delta-amiaolevulinate dehydratase polymorphism on lead body burden. Environ Health Perspect 1994:102(suppl 3):215-9.
7. Morris V, Markowitz ME, Rosen JF. Serial measurements of aminolevulinic acid dehydratase in children with lead toxicity. J Pediatr 1988;112: 916-9.
8. Schwartz J, Otto D. Lead and minor hearing impairment. Arch Environ Health 1991;46:300-5.
9. Holdstein Y, Pratt H, Goldsher M. Rosen G, Shenhav R, Linn S, et al. Auditory brainstem evoked potentials in asymptomatic lead-exposed subjects. J Laryngol Otol 1986;100:1031-6.
10. Poulos L, Qammaz S, Athanaselis S, Maravelias C, Koutselinis A. Statistically significant hematopoietic effects of low blood lead levels. Arch Environ Health 1986;41:384-6.
11. Staessen JA, Lauwerys RR, Buchet J-P, Bulpitt CJ, Rondia D, Vanrenterghem Y, et al. Impairment of renal function with increasing blood lead concentrations in the general population. N Engl J Med 1992;327: 151-6.
12. Hu H. A 50-year follow-up of childhood plumbism: hypertension, renal function and hemoglobin levels among survivors. Am J Dis Child 1991; 145:681-7.
13. National Research Council. Measuring lead exposure in infants, children and other sensitive populations. Washington, DC: National Academy Press, 1993.
14. Pueschel S, Linakis JG, Anderson AC. Lead poisoning in childhood. Baltimore: Paul H Brookes, 1996.
15. Piomelli S, Rosen JF, Chisolm J, Graef JW. Management of childhood lead poisoning. J Pediatr 1984;105:523-32.
16. Centers for Disease Control. Preventing lead poisoning in children. Atlanta, GA: Department of Health and Human Services, Public Health Service. 1991:51-64.
17. American Academy of Pediatrics' Committee on Drugs. Treatment guidelines for lead exposure in children. Pediatrics 1995;96(pt 1):155-60.
18. Graziano JH, Lolacono NJ, Moulton T, Mitchell ME, Slavkovick V, Zarate C. Controlled study of meso-2,3-dimercaptosuccininc acid for the management of childhood lead intoxication. J Pediatr 1992;120:133-9.
19. Chisolm JJ. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. Clin Toxicol 1992;30:493-504.
20. Chisolm JJ. The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediatr 1968;73:1-38.
21. Sachs HK, Blanksma LA, Murray EF, O'Connell MJ. Ambulatory treatment of lead poisoning: report of 1155 cases. Pediatrics 1970;46:389-96.
22. Vitale LF, Rosalinas-Bailon A, Folland D, Brennan JF, McCormick B. Oral penicillamine therapy for chronic lead poisoning in children. J Pediatr 1973;83:1041-5.
23. Molina-Ballesteros G, Zuniga-Charles MA, Sanchez-Anzaldo FJ, Gonzalez-Ramirez JD. Urinary delta-aminolevulinic acid as a biological indicator throughout penicillamine therapy in lead intoxication. Arch Environ Health 1978;33:308-13.
24. Shannon M, Graef J, Lovejoy FH. Efficacy and toxicity of d-penicillamine in low-level lead poisoning. J Pediatr 1988;112:799-804.
25. Liebelt EL, Shannon MW. Oral chelators for childhood lead poisoning. Pediatr Ann 1994;23:616-9,623-6.
26. Graziano JH, Lolacono NJ. Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J Pediatr 1988;113:751-7.
27. Bartsocas CS, Grunt JA, Boylen GW Jr, Brandt IK. Oral d-penicillamine and intramuscular BAL + EDTA in the treatment of lead accumulation. Acta Paediatr Scand 1971;60:553-8.
28. Shannon M, Grace A. Graef JW. Use of penicillamine in children with small lead burdens. N Engl J Med 1989;321:979-80.
29. Levy RS, Fisher M, Alter JN. Penicillamine: review and cutaneous manifestations. J Am Acad Dermatol 1983;8:548-58.
30. Camp AV. Hematologic toxicity from penicillamine in rheumatoid arthritis. J Rheumatol 1981;8(suppl 7):164-5.
31. Epstein O, DeVilliers D, Jain S, Potter BJ, Thomas HC, Sherlock S. Reduction of immune complexes and immunoglobulins induced by d-penicillamine in primary biliary cirrhosis. N Engl J Med 1979;300:274-8.
32. Khalil-Manesh F, Gonick HC, Cohen A, Bergaaschi E, Mutti A. Experimental model of lead nephropathy. II. Effect of removal from lead exposure and chelation treatment with dimercaptosuccininc acid (DMSA). Environ Res 1992;58:35-54.
33. Hammond C. Lead kinetics. In: Chisolm JJ, O'Hara DM, eds. Lead absorption in children: management, clinical and environmental aspects. Baltimore: Urban & Schwarzenberg, 1982:79-101.